A Phase 1 interventional study of ianalumab in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Arthritis, Rheumatoid by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.
Among the 30 studies in Arthritis, Rheumatoid by Novartis, this one is the 26th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 1, and was the 26th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 30 studies in Arthritis, Rheumatoid by Novartis is open now. Recruiting first, the newest first:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 7
First in 2002; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 98 across the 30 interventional studies. Of the 26 that completed or were terminated, 17 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Arthritis, Rheumatoid by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and pharmacokinetic comparability of two VAY736 drug products in patients with rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Powder for solution for injection / infusion
Biological: ianalumab
Solution for injection
Biological: ianalumab
Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
Also known as: VAY736
Safety and tolerability as measured by the number of patients with adverse events
The number of patients with adverse events after repeated subcutaneous (s.c) injections of a fixed dose of ianalumab
Time frame: Week 0 - 112
Pharmacokinetic comparability at steady state - AUCtau
The area under the serum ianalumab concentration-time curve from time zero to the end of the dosing interval (AUCtau)
Time frame: Week 8 - 12
Pharmacokinetic comparability at steady state - Cmax
Observed maximum serum concentration of ianalumab following drug administration (Cmax)
Time frame: Week 8 - 12
Pharmacokinetic comparability after the first dose - AUCtau
The area under the serum ianalumab concentration-time curve from time zero to the end of the dosing interval (AUCtau)
Time frame: Week 0 - 4
Pharmacokinetic comparability after the first dose - Cmax
Observed maximum serum concentration of ianalumab following drug administration (Cmax)
Time frame: Week 0 - 4
Pharmacokinetic comparability after the first dose - Tmax
Time to reach the maximum concentration after drug administration (Tmax)
Time frame: Week 0 - 4
Pharmacokinetic comparability of two ianalumab drug products after the last dose - AUCinf
The area under the serum ianalumab concentration-time curve from time zero to infinity (AUCinf)
Time frame: Week 8 - 12
Pharmacokinetic comparability after the last dose - Tmax
Time to reach the maximum concentration after drug administration (Tmax)
Time frame: Week 8 - 12
Pharmacokinetic comparability after the last dose - T1/2
The terminal elimination half-life (T1/2)
Time frame: Week 8 - 12
Pharmacokinetic comparability at the end of each dosing interval - Ctrough
Observed minimum serum ianalumab concentration following drug administration (Ctrough)
Time frame: Week 0 - 12
Pharmacodynamic effect as measured by B-cell level
Circulating B cells (CD19+)
Time frame: Week 0 - 112
Immunogenicity as measured by Anti-Drug Antibodies
Anti-ianalumab antibodies (ADA); incidence of ADA positive patients and correlation with AEs, PK and clinical outcomes
Time frame: Week 0 - 112
Plan to share: No
Ran from Dec 2018 to primary completion in Jul 2024, 66 months.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 66 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab